Brief: LianBio Reports Q4 Loss Per Share Of $0.17

LianBio

27/03/2023 13:59

March 27 (Reuters) - LianBio  LIAN.O :
    * REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL
RESULTS AND
PROVIDES CORPORATE UPDATE
    * PHASE 3 REGISTRATIONAL TRIAL OF TP-03 IN CHINESE PATIENTS
WITH
DEMODEX BLEPHARITIS ONGOING, WITH DATA EXPECTED IN Q4 OF 2023
    * CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AT
DECEMBER 31,
2022 TOTALED $302.4 MILLION
    * CURRENT CASH RUNWAY IS PROJECTED TO EXTEND THROUGH END OF
2024
    * PROJECTS ITS CASH POSITION IS SUFFICIENT TO FUND CURRENT
OPERATIONS THROUGH END OF 2024
    * QTRLY LOSS PER SHARE $0.17
    * Q4 EARNINGS PER SHARE VIEW $-0.27 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX4SDvWs 
Further company coverage:  LIAN.O 

 ((Reuters.Briefs@thomsonreuters.com;))